1459230-07-9

Upstream product

• 1199556-91-6 2-((1s,3s)-3-hydroxy-3-methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutyl)isoindoline-1,3-dione 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1459230-08-0 (1s,3s)-3-amino-1-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclobutanol 

Downstream Products

• 1459230-01-3 6-(4-((1s,3s)-1-amino-3-hydroxy-3-methylcyclobutyl)phenyl)-7-methyl-5-(pyridin-2-yl)-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
• 1459230-49-9 tert-butyl ((1s,3s)-1-(4-(5-bromo-4-oxo-3-(2,2,2-trifluoroethyl)-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-hydroxy-3-methylcyclobutyl)carbamate 
• 1459230-50-2 tert-butyl ((1s,3s)-3-hydroxy-3-methyl-1-(4-(4-oxo-5-(pyridin-2-yl)-3-(2,2,2-trifluoroethyl)-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)phenyl)cyclobutyl)carbamate 
• 1459230-02-4 6-(4-((1s,3s)-1-amino-3-hydroxy-3-methylcyclobutyl)phenyl)-5-(pyridin-2-yl)-3-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1459229-88-9 6-(4-((1s,3s)-1-amino-3-hydroxy-3-methylcyclobutyl)phenyl)-5-phenyl-3-(2,2,2-trifluoroethyl)furo[2,3-d]pyrimidin-4(3H)-one 
• 1459230-45-5 tert-butyl ((1s,3s)-3-hydroxy-3-methyl-1-(4-(7-methyl-4-oxo-5-(pyridin-2-yl)-3-(2,2,2-trifluoroethyl)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)cyclobutyl)carbamate 
• 1459230-48-8 tert-butyl ((1s,3s)-3-hydroxy-3-methyl-1-(4-(4-oxo-3-(2,2,2-trifluoroethyl)-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)phenyl)cyclobutyl)carbamate 
• 1459230-06-8 tert-butyl ((1s,3s)-3-hydroxy-3-methyl-1-(4-(4-oxo-5-phenyl-3-(2,2,2-trifluoroethyl)-3,4-dihydrofuro[2,3-d]pyrimidin-6-yl)phenyl)cyclobutyl)carbamate 

Relevant academic research and scientific papers

6- (4- (1 -AMINO- 3 -HYDROXYCYCLOBUTYL) PHENYL) - 5 - PHENYL (FURO, THIENO OR PYRROLO) [2, 3-D] PYRIMIDIN- 4 - ONE DERIVATIVES FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of one or more isoforms of the serine / threonine kinase AKT. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.